Transplantation Biology Research Center, Massachusetts General Hospital, Boston, MA, USA.
Transplantation. 2010 Feb 27;89(4):417-26. doi: 10.1097/TP.0b013e3181ca8848.
Clinical intestinal transplantation (Int-Tx) is limited by high rates of rejection, infection, and graft versus host disease. To improve clinical outcomes and eliminate the comorbidities associated with chronic immunosuppression, the induction of donor-specific tolerance to intestinal grafts is desirable, especially in the pediatric population. This study determined the ability of intestinal grafts to facilitate tolerance induction in major histocompatibility complex (MHC)-inbred miniature swine.
Seven MGH-miniature swine received heterotopic intestinal grafts, two across MHC-matched, minor-antigen disparities, three across a class I MHC disparity with 12 days of cyclosporine A, and two across a class I MHC disparity without an immunosuppressant. Chimerism was assessed by FACS analysis and immunohistochemistry. Cell-mediated lympholysis assays were used to assess antidonor responses.
Two animals receiving intestinal grafts without an immunosuppressant developed antidonor IgG in 14 days and rejected these completely. All other grafts were accepted with 12 days of cyclosporine A across both MHC-matched and MHC class I barriers. Cell-mediated lympholysis assays showed donor-specific unresponsiveness by day 30 across MHC class I barriers. Greater than 15% peripheral donor cell chimerism persisted for more than 60 days after MHC-matched Int-Tx. Although less than 1.5% peripheral donor cell chimerism was seen during the maintenance period after class I-mismatched Int-Tx, 5% to 10% myeloid chimerism was found in the peripheral blood 14 to 90 days after Int-Tx. FACS analysis demonstrated that 1% to 2% of lymphocytes in the graft mesenteric lymph nodes were CD4/CD25(HIGH+)/Foxp3(+) cells.
To our knowledge, this is the first demonstration of tolerance induction and persistence of chimerism in a large animal intestinal transplant model.
临床肠道移植(Int-Tx)受到排斥、感染和移植物抗宿主病发生率高的限制。为了改善临床结果并消除与慢性免疫抑制相关的合并症,诱导对肠道移植物的供体特异性耐受是理想的,特别是在儿科人群中。本研究旨在确定肠道移植物在 MHC 同基因小型猪中诱导耐受的能力。
7 只 MGH-小型猪接受了异位肠道移植物,2 只移植物跨越 MHC 匹配、次要抗原差异,3 只移植物跨越 I 类 MHC 差异,使用 12 天环孢素 A,2 只移植物跨越 I 类 MHC 差异,无免疫抑制剂。通过 FACS 分析和免疫组织化学评估嵌合性。细胞介导的淋巴细胞溶解试验用于评估抗供体反应。
2 只未接受免疫抑制剂的肠道移植物接受者在 14 天内产生抗供体 IgG,并完全排斥这些移植物。所有其他移植物在接受 MHC 匹配和 MHC I 类屏障时,均在 12 天的环孢素 A 治疗下被接受。细胞介导的淋巴细胞溶解试验显示,在 MHC I 类屏障上,在第 30 天出现供体特异性无反应性。在 MHC 匹配的 Int-Tx 后超过 60 天,外周供体细胞嵌合率持续超过 15%。尽管在 I 类错配 Int-Tx 后的维持期观察到的外周供体细胞嵌合率小于 1.5%,但在 Int-Tx 后 14 至 90 天,在外周血中发现 5%至 10%髓样嵌合。FACS 分析表明,移植物肠系膜淋巴结中的 1%至 2%淋巴细胞为 CD4/CD25(HIGH+)/Foxp3(+)细胞。
据我们所知,这是首次在大型动物肠道移植模型中证明诱导耐受和嵌合持续存在。